BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3115020)

  • 21. Effect of oestrogen on gonadotrophin release in stumptailed monkeys (Macaca arctoides) treated chronically with an agonist analogue of luteinizing hormone releasing hormone.
    Fraser HM
    J Endocrinol; 1981 Dec; 91(3):525-30. PubMed ID: 6799604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
    Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T
    Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Successful treatment of endometriosis in women with continuous subcutaneous infusion of gonadotropin-releasing hormone agonist (GnRH-A)].
    Masaoka K; Kitazawa M; Kumasaka T
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):405-11. PubMed ID: 2501437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
    Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
    J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Escape from the down-regulation of the pituitary-ovarian axis following decreased infusion of luteinizing hormone-releasing hormone agonist.
    Lemay A; Sandow J; Quesnel G; Bergeron J; Mérat P
    Fertil Steril; 1988 May; 49(5):802-8. PubMed ID: 3129314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Administration of nasal Buserelin as compared with subcutaneous Buserelin implant for endometriosis.
    Donnez J; Nisolle-Pochet M; Clerckx-Braun F; Sandow J; Casanas-Roux F
    Fertil Steril; 1989 Jul; 52(1):27-30. PubMed ID: 2501110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human inhibin-A administered early in the menstrual cycle alters concurrent pituitary and follicular, plus subsequent luteal, function in rhesus monkeys.
    Molskness TA; Woodruff TK; Hess DL; Dahl KD; Stouffer RL
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4002-6. PubMed ID: 8923851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of chronic luteinizing hormone-releasing hormone agonist treatment on dysfunctional uterine bleeding in the stumptailed macaque.
    Fraser HM; Shaw RW
    Acta Endocrinol (Copenh); 1984 Jul; 106(3):381-6. PubMed ID: 6429990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N; Bastide A
    Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Active immunization of stumptailed macaque monkeys against luteinizing hormone releasing hormone, and its effects on menstrual cycles, ovarian steroids and positive feedback.
    Fraser HM
    J Reprod Immunol; 1983 May; 5(3):173-83. PubMed ID: 6408251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversible estrous cycle suppression in prepubertal female rabbits treated with slow-release deslorelin implants.
    Geyer A; Daub L; Otzdorff C; Reese S; Braun J; Walter B
    Theriogenology; 2016 Jan; 85(2):282-7. PubMed ID: 26489909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term suppression of ovarian function by a luteinizing-hormone releasing hormone agonist implant in patients with endometriosis.
    Fraser HM; Sandow J; Cowen GM; Lumsden MA; Haining R; Smith SK
    Fertil Steril; 1990 Jan; 53(1):61-8. PubMed ID: 2104808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic hyperestrogenemia: lack of positive feedback action on gonadotropin-releasing hormone-induced luteinizing hormone release and dual site of negative feedback action.
    Richardson DW; Gordon K; Billiar RB; Little AB
    Endocrinology; 1992 Mar; 130(3):1090-6. PubMed ID: 1537275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pituitary and ovarian suppression rate after high dosage of gonadotropin-releasing hormone agonist.
    Bider D; Ben-Rafael Z; Shalev J; Goldenberg M; Mashiach S; Blankstein J
    Fertil Steril; 1989 Apr; 51(4):578-81. PubMed ID: 2494078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockade of LH and FSH secretion by LH-releasing hormone, by the LH-releasing hormone analogue, buserelin, and by combined treatment with LH-releasing hormone and oestradiol benzoate.
    Schuiling GA; Pols-Valkhof N; van der Schaaf-Verdonk GC; Koiter TR
    J Endocrinol; 1984 Dec; 103(3):301-9. PubMed ID: 6438265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
    Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
    Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of pituitary-gonadal suppression with a gonadotrophin-releasing hormone agonist on fetal gonadotrophin secretion, fetal gonadal development and maternal steroid secretion in the sheep.
    Thomas GB; McNeilly AS; Gibson F; Brooks AN
    J Endocrinol; 1994 May; 141(2):317-24. PubMed ID: 8046302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relation between pharmacokinetics and endocrine effects of buserelin implants in patients with mastalgia.
    Klijn JG; van Geel B; de Jong FH; Sandow J; Krauss B
    Clin Endocrinol (Oxf); 1991 Apr; 34(4):253-8. PubMed ID: 1908753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization.
    Bentick B; Shaw RW; Iffland CA; Burford G; Bernard A
    Fertil Steril; 1988 Jul; 50(1):79-84. PubMed ID: 3133251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.